MorphoSys AG buy Commando
Summary
This prediction ended on 03.05.20 with a price of €93.88. With a performance of -9.56%, the BUY prediction for MorphoSys AG by Commando closed slightly in the red. Commando has 50% into this predictionMorphoSys is a German biopharmaceutical company that develops innovative therapies for the treatment of cancer, autoimmune diseases, and other serious illnesses. The company specializes in developing monoclonal antibodies, which are highly specific and targeted therapies that recognize and bind to specific cancer cells or disease-causing proteins in the body. MorphoSys has a diverse pipeline of products in various stages of development, including several drugs that have shown promising results in clinical trials. The company is listed on the Frankfurt and NASDAQ stock exchanges and has a market capitalization of over $4 billion.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
MorphoSys AG | - | - | - | - |
iShares Core DAX® | 2.147% | 2.681% | 17.410% | 16.694% |
iShares Nasdaq 100 | -0.578% | -0.816% | 24.107% | 34.957% |
iShares Nikkei 225® | 0.635% | 3.079% | 16.921% | 11.023% |
iShares S&P 500 | 0.746% | 0.171% | 23.802% | 37.315% |
Comments by Commando for this prediction
In the thread Morphosys AG diskutieren
In the thread Trading Morphosys AG